News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Celgene (CELG) Release: Data Presented At ESMO 2017 Further Evaluate Role Of ABRAXANE For Patients With Historically Challenging Cancers



9/8/2017 6:44:50 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

Multiple presentations evaluate the investigational uses of ABRAXANE alone or as combination therapy to treat non-small cell lung cancer and as combination therapy for locally advanced pancreatic cancer

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that data from multiple studies evaluating investigational uses of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) will be presented during the European Society of Medical Oncology (ESMO) 2017 Annual Meeting between September 8-12 in Madrid, Spain.

"The data presented at ESMO highlight investigational uses of ABRAXANE to potentially treat patients with particularly challenging diseases, either alone or in combination with other agents," said Nadim Ahmed, President, Hematology and Oncology for Celgene. "Through these data, we are able to continue advancing our understanding and treatment of these cancers especially in patient populations with historically limited treatment options."

In advanced non-small cell lung cancer (NSCLC), abstracts from three studies in the ABOUND program continue to evaluate investigational uses of ABRAXANE. ABOUND 2L+ is a Phase II trial evaluating second-line monotherapy or combination treatment with an immune checkpoint inhibitor or epigenetic therapy. ABOUND.SQM is a Phase III study evaluating ABRAXANE as combination treatment with carboplatin as induction therapy for those with squamous disease. ABOUND 70+ is a Phase IV study evaluating the first-line treatment of ABRAXANE + carboplatin in patients 70 years and older.

Additionally, updated data from the Phase II LAPACT study evaluating the investigational use of ABRAXANE in patients with locally advanced, non-resectable pancreatic cancer will be presented.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES